29 results on '"Morten Tulstrup"'
Search Results
2. TET2 mutations are associated with hypermethylation at key regulatory enhancers in normal and malignant hematopoiesis
- Author
-
Morten Tulstrup, Mette Soerensen, Jakob Werner Hansen, Linn Gillberg, Maria Needhamsen, Katja Kaastrup, Kristian Helin, Kaare Christensen, Joachim Weischenfeldt, and Kirsten Grønbæk
- Subjects
Science - Abstract
TET2 mutations are frequent in myeloid malignancies and in elderly individuals with or without cytopenia. Here, the authors analyse the association between TET2 mutations and methylation changes in healthy elderly twins and patients with cytopenia and compare them to those from leukemia.
- Published
- 2021
- Full Text
- View/download PDF
3. Clonal Hematopoiesis and Epigenetic Age Acceleration in Elderly Danish Twins
- Author
-
Mette Soerensen, Morten Tulstrup, Jakob Werner Hansen, Joachim Weischenfeldt, Kirsten Grønbæk, and Kaare Christensen
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Clonal hematopoiesis of indeterminate potential (CHIP) is common in the elderly and has been reported to associate with accelerated epigenetic age (AgeAccel), especially intrinsic (ie, cell-type independent) AgeAccel and to a lesser degree extrinsic AgeAccel, which reflects the immune-cell composition of the peripheral blood. We investigated the association between CHIP occurrence and AgeAccel in 154 Danish twin pairs aged 73–90 years (mean 79), using both individual-level and intrapair analyses, the latter to control for shared genetic and environmental factors. Of 308 individuals, 116 carried a CHIP mutation. CHIP carriers had non-significantly increased AgeAccel compared with non-carriers; the strongest association was for the Intrinsic Epigenetic Age Acceleration (IEAA) estimator (CHIP carriers 1.4 years older, P = 0.052). In intrapair analyses, the extrinsic Hannum age estimator showed the strongest association (1.6 years older, P = 0.027). In mutation-specific analyses, TET2 mutations were associated with the extrinsic Hannum age estimator in both individual-level (3.0 years older, P = 0.003) and intrapair analyses (2.8 years older, P = 0.05). DNMT3A mutations were associated with IEAA in individual-level (1.9 years older, P = 0.034) but not intrapair analysis (0.9 years, P = 0.41). Analyses of logit-transformed variant allele frequency were generally consistent with these results. Together, these observations indicate that different factors may be driving the expansion of DNMT3A and TET2 clones, respectively. Finally, CHIP carriers accelerated in both the Hannum and the GrimAge age estimators did not have an increased mortality risk in our cohort followed for 22 years (HR = 1.02, P = 0.93), hence not replicating the stratification model proposed by Nachun et al.
- Published
- 2022
- Full Text
- View/download PDF
4. Acute and persistent symptoms in non-hospitalized PCR-confirmed COVID-19 patients
- Author
-
Sofie Bliddal, Karina Banasik, Ole Birger Pedersen, Janna Nissen, Lisa Cantwell, Michael Schwinn, Morten Tulstrup, David Westergaard, Henrik Ullum, Søren Brunak, Niels Tommerup, Bjarke Feenstra, Frank Geller, Sisse Rye Ostrowski, Kirsten Grønbæk, Claus Henrik Nielsen, Susanne Dam Nielsen, and Ulla Feldt-Rasmussen
- Subjects
Medicine ,Science - Abstract
Abstract Reports of persistent symptoms after hospitalization with COVID-19 have raised concern of a “long COVID” syndrome. This study aimed at determining the prevalence of and risk factors for acute and persistent symptoms in non-hospitalized patients with polymerase chain reaction (PCR) confirmed COVID-19. We conducted a cohort study of non-hospitalized participants identified via the Danish Civil Registration System with a SARS-CoV-2-positive PCR-test and available biobank samples. Participants received a digital questionnaire on demographics and COVID-19-related symptoms. Persistent symptoms: symptoms > 4 weeks (in sensitivity analyses > 12 weeks). We included 445 participants, of whom 34% were asymptomatic. Most common acute symptoms were fatigue, headache, and sneezing, while fatigue and reduced smell and taste were most severe. Persistent symptoms, most commonly fatigue and memory and concentration difficulties, were reported by 36% of 198 symptomatic participants with follow-up > 4 weeks. Risk factors for persistent symptoms included female sex (women 44% vs. men 24%, odds ratio 2.7, 95% CI 1.4–5.1, p = 0.003) and BMI (odds ratio 1.1, 95% CI 1.0–1.2, p = 0.001). In conclusion, among non-hospitalized PCR-confirmed COVID-19 patients one third were asymptomatic while one third of symptomatic participants had persistent symptoms illustrating the heterogeneity of disease presentation. These findings should be considered in health care planning and policy making related to COVID-19.
- Published
- 2021
- Full Text
- View/download PDF
5. Trypsin-encoding PRSS1-PRSS2 variations influence the risk of asparaginase-associated pancreatitis in children with acute lymphoblastic leukemia: a Ponte di Legno toxicity working group report
- Author
-
Benjamin O. Wolthers, Thomas L. Frandsen, Chirag J. Patel, Rachid Abaji, Andishe Attarbaschi, Shlomit Barzilai, Antonella Colombini, Gabriele Escherich, Marie Grosjean, Maja Krajinovic, Eric Larsen, Der-Cherng Liang, Anja Möricke, Kirsten K. Rasmussen, Sujith Samarasinghe, Lewis B. Silverman, Inge M. van der Sluis, Martin Stanulla, Morten Tulstrup, Rachita Yadav, Wenjian Yang, Ester Zapotocka, Ramneek Gupta, and Kjeld Schmiegelow
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Asparaginase-associated pancreatitis is a life-threatening toxicity to childhood acute lymphoblastic leukemia treatment. To elucidate genetic predisposition and asparaginase-associated pancreatitis pathogenesis, ten trial groups contributed remission samples from patients aged 1.0−17.9 years treated for acute lymphoblastic leukemia between 2000 and 2016. Cases (n=244) were defined by the presence of at least two of the following criteria: (i) abdominal pain; (ii) levels of pancreatic enzymes ≥3 × upper normal limit; and (iii) imaging compatible with pancreatitis. Controls (n=1320) completed intended asparaginase therapy, with 78% receiving ≥8 injections of pegylated-asparaginase, without developing asparaginase-associated pancreatitis. rs62228256 on 20q13.2 showed the strongest association with the development of asparaginase-associated pancreatitis (odds ratio=3.75; P=5.2×10−8). Moreover, rs13228878 (OR=0.61; P=7.1×10−6) and rs10273639 (OR=0.62; P=1.1×10−5) on 7q34 showed significant association with the risk of asparaginase-associated pancreatitis. A Dana Farber Cancer Institute ALL Consortium cohort consisting of patients treated on protocols between 1987 and 2004 (controls=285, cases=33), and the Children’s Oncology Group AALL0232 cohort (controls=2653, cases=76) were available as replication cohorts for the 20q13.2 and 7q34 variants, respectively. While rs62228256 was not validated as a risk factor (P=0.77), both rs13228878 (P=0.03) and rs10273639 (P=0.04) were. rs13228878 and rs10273639 are in high linkage disequilibrium (r2=0.94) and associated with elevated expression of the PRSS1 gene, which encodes for trypsinogen, and are known risk variants for alcohol-associated and sporadic pancreatitis in adults. Intra-pancreatic trypsinogen cleavage to proteolytic trypsin induces autodigestion and pancreatitis. In conclusion, this study finds a shared genetic predisposition between asparaginase-associated pancreatitis and non-asparaginase-associated pancreatitis, and targeting the trypsinogen activation pathway may enable identification of effective interventions for asparaginase-associated pancreatitis.
- Published
- 2019
- Full Text
- View/download PDF
6. Impact of U2AF1 mutations on circular RNA expression in myelodysplastic neoplasms
- Author
-
Eileen Wedge, Ulvi Ahmadov, Thomas B. Hansen, Zongliang Gao, Morten Tulstrup, Christophe Côme, Sridhar Nonavinkere Srivatsan, Tanzir Ahmed, Jakob S. Jespersen, Balthasar C. Schlotmann, Claudia Schöllkopf, Klas Raaschou-Jensen, Niels Ødum, Jørgen Kjems, Rasmus O. Bak, Matthew J. Walter, Kirsten Grønbæk, and Lasse S. Kristensen
- Subjects
Cancer Research ,Mice ,Splicing Factor U2AF/genetics ,Oncology ,Doxycycline ,Neoplasms ,RNA Splicing ,RNA, Circular/genetics ,Mutation ,Animals ,Hematology ,RNA Splicing Factors/genetics ,Myelodysplastic Syndromes/genetics - Abstract
Mutations in U2AF1 are relatively common in myelodysplastic neoplasms (MDS) and are associated with an inferior prognosis, but the molecular mechanisms underlying this are not fully elucidated. Circular RNAs (circRNAs) have been implicated in cancer, but it is unknown how mutations in splicing factors may impact on circRNA biogenesis. Here, we used RNA-sequencing to investigate the effects of U2AF1 mutations on circRNA expression in K562 cells with a doxycycline-inducible U2AF1 S34 mutation, in a mouse model with a doxycycline-inducible U2AF1 S34 mutation, and in FACS-sorted CD34+ bone marrow cells from MDS patients with either U2AF1 S34 or U2AF1 Q157 mutations. In all contexts, we found an increase in global circRNA levels in the U2AF1-mutated setting, which was independent of expression changes in the cognate linear host genes. In patients, the U2AF1 S34 and U2AF1 Q157 mutations were both associated with an overall increased expression of circRNAs. circRNAs generated by a non-Alu-mediated mechanism generally showed the largest increase in expression levels. Several well-described cancer-associated circRNAs, including circZNF609 and circCSNK1G3, were upregulated in MDS patients with U2AF1 mutations compared to U2AF1-wildtype MDS controls. In conclusion, high circRNA expression is observed in association with U2AF1 mutations in three biological systems, presenting an interesting possibility for biomarker and therapeutic investigation.
- Published
- 2023
7. TET2 mutations are associated with hypermethylation at key regulatory enhancers in normal and malignant hematopoiesis
- Author
-
Maria Needhamsen, Jakob Werner Hansen, Morten Tulstrup, Mette Soerensen, Kaare Christensen, Katja Kaastrup, Kristian Helin, Kirsten Grønbæk, Joachim Weischenfeldt, and Linn Gillberg
- Subjects
Epigenomics ,Myeloid ,health care facilities, manpower, and services ,Science ,General Physics and Astronomy ,Biology ,Peripheral blood mononuclear cell ,General Biochemistry, Genetics and Molecular Biology ,Article ,Acute myeloid leukaemia ,DNA Methyltransferase 3A ,Dioxygenases ,hemic and lymphatic diseases ,medicine ,Humans ,DNA (Cytosine-5-)-Methyltransferases ,Enhancer ,Transcription factor ,Cancer genetics ,Cytopenia ,Multidisciplinary ,Myeloproliferative Disorders ,General Chemistry ,social sciences ,DNA Methylation ,medicine.disease ,Hematopoietic Stem Cells ,humanities ,Hematopoiesis ,DNA-Binding Proteins ,Haematopoiesis ,medicine.anatomical_structure ,Enhancer Elements, Genetic ,Risk factors ,DNA methylation ,Mutation ,Cancer research ,Stem cell ,Haematological diseases ,Transcription Factors - Abstract
Mutations in the epigenetic modifier TET2 are frequent in myeloid malignancies and clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of undetermined significance (CCUS). Here, we investigate associations between TET2 mutations and DNA methylation in whole blood in 305 elderly twins, 15 patients with CCUS and 18 healthy controls. We find that TET2 mutations are associated with DNA hypermethylation at enhancer sites in whole blood in CHIP and in both granulocytes and mononuclear cells in CCUS. These hypermethylated sites are associated with leukocyte function and immune response and ETS-related and C/EBP-related transcription factor motifs. While the majority of TET2-associated hypermethylation sites are shared between CHIP and in AML, we find a set of AML-specific hypermethylated loci at active enhancer elements in hematopoietic stem cells. In summary, we show that TET2 mutations is associated with hypermethylated enhancers involved in myeloid differentiation in both CHIP, CCUS and AML patients., TET2 mutations are frequent in myeloid malignancies and in elderly individuals with or without cytopenia. Here, the authors analyse the association between TET2 mutations and methylation changes in healthy elderly twins and patients with cytopenia and compare them to those from leukemia.
- Published
- 2021
8. Acquired Loss of a Sex Chromosome Is a Positive Prognostic Factor for Patients with Multiple Myeloma Undergoing ASCT
- Author
-
Simon Husby, Morten Tulstrup, Mads Harsløf, Christian Nielsen, Marianne Antonius Jakobsen, Eva Kannik Hastrup, Lene Hyldahl Ebbesen, Mette Klarskov Andersen, Maroulio Pertesi, Björn Nilsson, Carsten Utoft Niemann, Agoston Gyula Szabo, Niels Frost Andersen, Niels Abildgaard, Kirsten Grønbæk, and Annette Juul Vangsted
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Published
- 2022
9. Effects of NT5C2 Germline Variants on 6‐Mecaptopurine Metabolism in Children With Acute Lymphoblastic Leukemia
- Author
-
Takaya Moriyama, Morten Tulstrup, Chengcheng Liu, Kjeld Schmiegelow, Smita Bhatia, Kristine R. Crews, Wentao Yang, Mary V. Relling, Wenjian Yang, Chuang Jiang, William E. Evans, Ching-Hon Pui, Maoxiang Qian, Colton Smith, Hui Zhang, Ziping Li, and Jun J. Yang
- Subjects
Male ,Antimetabolites, Antineoplastic ,Linkage disequilibrium ,Erythrocytes ,Adolescent ,Mutation, Missense ,Single-nucleotide polymorphism ,Precursor T-Cell Lymphoblastic Leukemia-Lymphoma ,Polymorphism, Single Nucleotide ,030226 pharmacology & pharmacy ,Linkage Disequilibrium ,Article ,Germline ,Cohort Studies ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Transcription (biology) ,Genetic variation ,NT5C2 Gene ,Humans ,Pharmacology (medical) ,Child ,Thioguanine ,Enhancer ,5'-Nucleotidase ,Alleles ,Germ-Line Mutation ,Pharmacology ,Genetics ,Thiopurine methyltransferase ,biology ,Mercaptopurine ,Gene Expression Regulation, Neoplastic ,Child, Preschool ,Multigene Family ,030220 oncology & carcinogenesis ,Multivariate Analysis ,biology.protein ,Female ,Genome-Wide Association Study - Abstract
6-mercaptopurine (6-MP) is widely used in the treatment of acute lymphoblastic leukemia (ALL), and its cytotoxicity is primarily mediated by thioguanine nucleotide metabolites (TGN). Recent genome-wide association study has identified germline polymorphisms (e.g., rs72846714) in the NT5C2 gene associated with 6-MP metabolism in patients with ALL. However, the full spectrum of genetic variation in NT5C2 is unclear and its impact on 6-MP drug activation has not been comprehensively examined. To this end, we performed targeted sequencing of NT5C2 in 588 children with ALL and identified 121 single nucleotide polymorphisms (SNPs) nominally associated with erythrocyte TGN during 6-MP treatment (P < 0.05). Of these, 61 variants were validated in a replication cohort of 372 children with ALL. After considering linkage disequilibrium and multivariate analysis, we confirmed two clusters of variants, represented by rs72846714 and rs58700372, that independently affected 6-MP metabolism. Functional studies showed that rs58700372 directly altered the activity of an intronic enhancer, with the variant allele linked to higher transcription activity and reduced 6-MP metabolism (lower TGN). By contrast, rs72846714 was not located in a regulatory element and instead its association signal was explained by linkage disequilibrium with a proximal functional variant rs12256506 that activated NT5C2 transcription in-cis. Our results indicated that NT5C2 germline variation significantly contributes to inter-patient variability in thiopurine drug disposition.
- Published
- 2020
10. Effects of germline DHFR and FPGS variants on methotrexate metabolism and relapse of leukemia
- Author
-
Morten Tulstrup, Jonas Abrahamsson, Ramneek Gupta, Chuang Jiang, Hui Zhang, Lisa Lyngsie Hjalgrim, Kjeld Schmiegelow, Jacob Nersting, Bendik Lund, Jukka Kanerva, Marie Grosjean, Takaya Moriyama, Olafur G. Jonsson, Benjamin Ole Wolthers, Kathrine Grell, Goda Vaitkeviciene, Stine Nygaard Nielsen, Kaie Pruunsild, Ulrik Malthe Overgaard, Jun J. Yang, Rikke Linnemann Nielsen, and Petter Quist-Paulsen
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,Immunology ,Genome-wide association study ,Polymorphism, Single Nucleotide ,Biochemistry ,Young Adult ,Maintenance therapy ,Internal medicine ,Dihydrofolate reductase ,medicine ,Humans ,Dosing ,Peptide Synthases ,Child ,Chemotherapy ,Lymphoid Neoplasia ,Hematology ,biology ,business.industry ,Infant, Newborn ,Infant ,Cell Biology ,Middle Aged ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Prognosis ,medicine.disease ,Tetrahydrofolate Dehydrogenase ,Leukemia ,Methotrexate ,Polyglutamic Acid ,Child, Preschool ,biology.protein ,Cancer research ,Female ,Neoplasm Recurrence, Local ,business ,Genome-Wide Association Study ,medicine.drug - Abstract
Methotrexate (MTX) during maintenance therapy is essential for curing acute lymphoblastic leukemia (ALL), but dosing strategies aiming at adequate treatment intensity are challenged by interindividual differences in drug disposition. To evaluate genetic factors associated with MTX metabolism, we performed a genome-wide association study in 447 ALL cases from the Nordic Society for Pediatric Haematology and Oncology ALL2008 study, validating results in an independent set of 196 patients. The intergenic single-nucleotide polymorphism rs1382539, located in a regulatory element of DHFR, was associated with increased levels of short-chain MTX polyglutamates (P = 1.1 × 10−8) related to suppression of enhancer activity, whereas rs35789560 in FPGS (p.R466C, P = 5.6 × 10−9) was associated with decreased levels of long-chain MTX polyglutamates through reduced catalytic activity. Furthermore, the FPGS variant was linked with increased relapse risk (P = .044). These findings show a genetic basis for interpatient variability in MTX response and could be used to improve future dosing algorithms.
- Published
- 2020
11. Candidate single nucleotide polymorphisms and thromboembolism in acute lymphoblastic leukemia – A NOPHO ALL2008 study
- Author
-
Marissa LeBlanc, Ramneek Gupta, Cecilie Utke Rank, Morten Tulstrup, Olafur G. Jonsson, Pasi Huttunen, Birgitte Klug Albertsen, Sonata Saulyte Trakymiene, Rikke Linnemann Nielsen, Kirsten Brunsvig Jarvis, Susanna Ranta, Kadri Saks, Ruta Tuckuviene, Kjeld Schmiegelow, Ellen Ruud, HUS Children and Adolescents, Clinicum, and Children's Hospital
- Subjects
Male ,Lymphoblastic Leukemia ,CHILDREN ,Acute lymphoblastic leukemia ,VARIANTS ,030204 cardiovascular system & hematology ,0302 clinical medicine ,Risk Factors ,BLOOD-GROUP ,Medicine ,Cumulative incidence ,Prospective Studies ,Child ,education.field_of_study ,Hazard ratio ,ASSOCIATION ,Venous Thromboembolism ,Hematology ,Middle Aged ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,3. Good health ,DEVELOPMENTAL HEMOSTASIS ,Child, Preschool ,030220 oncology & carcinogenesis ,Female ,INCIDENT VENOUS THROMBOEMBOLISM ,Adult ,medicine.medical_specialty ,Adolescent ,Population ,Single-nucleotide polymorphism ,Polymorphism, Single Nucleotide ,Young Adult ,03 medical and health sciences ,Thromboembolism ,ABO blood group system ,Internal medicine ,Humans ,Genetic Predisposition to Disease ,education ,METAANALYSIS ,FIBRINOGEN ,business.industry ,Proportional hazards model ,Infant, Newborn ,Infant ,Single nucleotide polymorphisms ,Confidence interval ,THROMBOSIS ,3121 General medicine, internal medicine and other clinical medicine ,RISK-FACTORS ,business - Abstract
IntroductionThromboembolism is a serious toxicity of acute lymphoblastic leukemia treatment, and contributes to substantial morbidity and mortality. Several single nucleotide polymorphisms have been associated with thromboembolism in the general population; however, their impact in patients with acute lymphoblastic leukemia, particularly in children, remains uncertain.Materials and methodsWe collected constitutional DNA and prospectively registered thromboembolic events in 1252 patients, 1–45 years, with acute lymphoblastic leukemia included in the Nordic Society of Pediatric Hematology and Oncology ALL2008 protocol in the Nordic and Baltic countries (7/2008–7/2016). Based on previously published data and a priori power calculations, we selected four single nucleotide polymorphisms: F5 rs6025, F11 rs2036914, FGG rs2066865, and ABO rs8176719.ResultsThe 2.5 year cumulative incidence of thromboembolism was 7.1% (95% confidence interval (CI) 5.6–8.5). F11 rs2036914 was associated with thromboembolism (hazard ratio (HR) 1.52, 95%CI 1.11–2.07) and there was a borderline significant association for FGG rs2066865 (HR 1.37, 95%CI 0.99–1.91), but no association for ABO rs8176719 or F5 rs6025 in multiple cox regression. A genetic risk score based on F11 rs2036914 and FGG rs2066865 was associated with thromboembolism (HR 1.45 per risk allele, 95%CI 1.15–1.81), the association was strongest in adolescents 10.0–17.9 years (HR 1.64).ConclusionIf validated, a F11 rs2036914/FGG rs2066865 risk prediction model should be tested as a stratification tool for prevention of thromboembolism in patients with acute lymphoblastic leukemia. Introduction: Thromboembolism is a serious toxicity of acute lymphoblastic leukemia treatment, and contributes to substantial morbidity and mortality. Several single nucleotide polymorphisms have been associated with thromboembolism in the general population; however, their impact in patients with acute lymphoblastic leukemia, particularly in children, remains uncertain. Materials and methods: We collected constitutional DNA and prospectively registered thromboembolic events in 1252 patients, 1–45 years, with acute lymphoblastic leukemia included in the Nordic Society of Pediatric Hematology and Oncology ALL2008 protocol in the Nordic and Baltic countries (7/2008–7/2016). Based on previously published data and a priori power calculations, we selected four single nucleotide polymorphisms: F5 rs6025, F11 rs2036914, FGG rs2066865, and ABO rs8176719. Results: The 2.5 year cumulative incidence of thromboembolism was 7.1% (95% confidence interval (CI) 5.6–8.5). F11 rs2036914 was associated with thromboembolism (hazard ratio (HR) 1.52, 95%CI 1.11–2.07) and there was a borderline significant association for FGG rs2066865 (HR 1.37, 95%CI 0.99–1.91), but no association for ABO rs8176719 or F5 rs6025 in multiple cox regression. A genetic risk score based on F11 rs2036914 and FGG rs2066865 was associated with thromboembolism (HR 1.45 per risk allele, 95%CI 1.15–1.81), the association was strongest in adolescents 10.0–17.9 years (HR 1.64). Conclusion: If validated, a F11 rs2036914/FGG rs2066865 risk prediction model should be tested as a stratification tool for prevention of thromboembolism in patients with acute lymphoblastic leukemia.
- Published
- 2019
12. A predictive model for bone marrow disease in cytopenia based on noninvasive procedures
- Author
-
Dicte Træden, Morten Tulstrup, Jack Bernard Cowland, Lene Dissing Sjö, Martin Bøgsted, Kirsten Grønbæk, Mette Klarskov Andersen, and Jakob Werner Hansen
- Subjects
Bone Marrow ,Myelodysplastic Syndromes ,Mutation ,High-Throughput Nucleotide Sequencing ,Humans ,Anemia ,Hematology ,Bone Marrow Diseases - Abstract
Bone marrow specimens are the core of the diagnostic workup of patients with cytopenia. To explore whether next-generation sequencing (NGS) could be used to rule out malignancy without bone marrow specimens, we incorporated NGS in a model to predict presence of disease in the bone marrow of patients with unexplained cytopenia. We analyzed the occurrence of mutations in 508 patients with cytopenia, referred for primary workup of a suspected hematologic malignancy from 2015 to 2020. We divided patients into a discovery (n = 340) and validation (n = 168) cohort. Targeted sequencing, bone marrow biopsy, and complete blood count were performed in all patients. Mutations were identified in 267 (53%) and abnormal bone marrow morphology in 188 (37%) patients. Patients with isolated neutropenia had the lowest frequency of both mutations (21%) and abnormal bone marrow morphology (5%). The median number of mutations per patient was 2 in patients with abnormal bone marrow morphology compared with 0 in patients with a nondiagnostic bone marrow morphology (P < .001). In a multivariable logistic regression, mutations in TET2, SF3B1, U2AF1, TP53, and RUNX1 were significantly associated with abnormal bone marrow morphology. In the validation cohort, a model combining mutational status and clinical data identified 34 patients (20%) without abnormal bone marrow morphology with a sensitivity of 100% (95% confidence interval: 93%-100%). Overall, we show that NGS combined with clinical data can predict the presence of abnormal bone marrow morphology in patients with unexplained cytopenia and thus can be used to assess the need of a bone marrow biopsy.
- Published
- 2021
13. Acute and persistent symptoms in non-hospitalized PCR-confirmed COVID-19 patients
- Author
-
Ulla Feldt-Rasmussen, Søren Brunak, Ole Birger Pedersen, Kirsten Grønbæk, Lisa Cantwell, Frank Geller, Niels Tommerup, Susanne Dam Nielsen, Bjarke Feenstra, Henrik Ullum, Sisse R. Ostrowski, Michael Schwinn, Janna Nissen, Karina Banasik, David Westergaard, Morten Tulstrup, Sofie Bliddal, and Claus Henrik Nielsen
- Subjects
Adult ,Male ,medicine.medical_specialty ,Epidemiology ,Science ,030204 cardiovascular system & hematology ,Polymerase Chain Reaction ,Asymptomatic ,Article ,Body Mass Index ,Comorbidities ,Cohort Studies ,03 medical and health sciences ,Sex Factors ,0302 clinical medicine ,Surveys and Questionnaires ,Internal medicine ,medicine ,Humans ,030212 general & internal medicine ,Signs and symptoms ,Fatigue ,Public health ,Multidisciplinary ,business.industry ,COVID-19 ,Odds ratio ,Middle Aged ,Health policy ,Risk factors ,Viral infection ,Outcomes research ,Disease Presentation ,Acute Disease ,Infectious diseases ,Medicine ,Female ,medicine.symptom ,business ,Body mass index ,Cohort study - Abstract
Reports of persistent symptoms after hospitalization with COVID-19 have raised concern of a “long COVID” syndrome. This study aimed at determining the prevalence of and risk factors for acute and persistent symptoms in non-hospitalized patients with polymerase chain reaction (PCR) confirmed COVID-19. We conducted a cohort study of non-hospitalized participants identified via the Danish Civil Registration System with a SARS-CoV-2-positive PCR-test and available biobank samples. Participants received a digital questionnaire on demographics and COVID-19-related symptoms. Persistent symptoms: symptoms > 4 weeks (in sensitivity analyses > 12 weeks). We included 445 participants, of whom 34% were asymptomatic. Most common acute symptoms were fatigue, headache, and sneezing, while fatigue and reduced smell and taste were most severe. Persistent symptoms, most commonly fatigue and memory and concentration difficulties, were reported by 36% of 198 symptomatic participants with follow-up > 4 weeks. Risk factors for persistent symptoms included female sex (women 44% vs. men 24%, odds ratio 2.7, 95% CI 1.4–5.1, p = 0.003) and BMI (odds ratio 1.1, 95% CI 1.0–1.2, p = 0.001). In conclusion, among non-hospitalized PCR-confirmed COVID-19 patients one third were asymptomatic while one third of symptomatic participants had persistent symptoms illustrating the heterogeneity of disease presentation. These findings should be considered in health care planning and policy making related to COVID-19.
- Published
- 2021
14. Trypsin-encoding PRSS1-PRSS2 variations influence the risk of asparaginase-associated pancreatitis in children with acute lymphoblastic leukemia: a Ponte di Legno toxicity working group report
- Author
-
Lewis B. Silverman, Marie Grosjean, Chirag J. Patel, Wenjian Yang, Morten Tulstrup, Benjamin Ole Wolthers, Rachita Yadav, Eric Larsen, Kjeld Schmiegelow, Thomas Frandsen, Ramneek Gupta, Rachid Abaji, Inge M. van der Sluis, Anja Möricke, Sujith Samarasinghe, Maja Krajinovic, Der-Cherng Liang, Antonella Colombini, Andishe Attarbaschi, Shlomit Barzilai, Gabriele Escherich, Kirsten K. Rasmussen, Martin Stanulla, and Ester Zapotocka
- Subjects
Male ,medicine.medical_specialty ,Asparaginase ,Adolescent ,Genotype ,Trypsinogen ,Antineoplastic Agents ,Gastroenterology ,Models, Biological ,Polymorphism, Single Nucleotide ,Article ,Polyethylene Glycols ,chemistry.chemical_compound ,SDG 3 - Good Health and Well-being ,Internal medicine ,medicine ,Genetic predisposition ,PRSS2 ,Humans ,Genetic Predisposition to Disease ,Trypsin ,Trypsinogen activation ,Child ,Childhood Acute Lymphoblastic Leukemia ,Alleles ,Genetic Association Studies ,business.industry ,Genetic Variation ,Infant ,Hematology ,Odds ratio ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,medicine.disease ,Acute Lymphoblastic Leukemia ,Phenotype ,chemistry ,Pancreatitis ,Child, Preschool ,Female ,business - Abstract
Asparaginase-associated pancreatitis is a life-threatening toxicity to childhood acute lymphoblastic leukemia treatment. To elucidate genetic predisposition and asparaginase-associated pancreatitis pathogenesis, ten trial groups contributed remission samples from patients aged 1.0−17.9 years treated for acute lymphoblastic leukemia between 2000 and 2016. Cases (n=244) were defined by the presence of at least two of the following criteria: (i) abdominal pain; (ii) levels of pancreatic enzymes ≥3 x upper normal limit; and (iii) imaging compatible with pancreatitis. Controls (n=1320) completed intended asparaginase therapy, with 78% receiving ≥8 injections of pegylated-asparaginase, without developing asparaginase-associated pancreatitis. rs62228256 on 20q13.2 showed the strongest association with the development of asparaginase-associated pancreatitis (odds ratio=3.75; P=5.2x10 -8 ). Moreover, rs13228878 (OR=0.61; P=7.1x10 -6 ) and rs10273639 (OR=0.62; P=1.1x10 -5 ) on 7q34 showed significant association with the risk of asparaginase-associated pancreatitis. A Dana Farber Cancer Institute ALL Consortium cohort consisting of patients treated on protocols between 1987 and 2004 (controls=285, cases=33), and the Children’s Oncology Group AALL0232 cohort (controls=2653, cases=76) were available as replication cohorts for the 20q13.2 and 7q34 variants, respectively. While rs62228256 was not validated as a risk factor (P=0.77), both rs13228878 (P=0.03) and rs10273639 (P=0.04) were. rs13228878 and rs10273639 are in high linkage disequilibrium (r 2 =0.94) and associated with elevated expression of the PRSS1 gene, which encodes for trypsinogen, and are known risk variants for alcohol-associated and sporadic pancreatitis in adults. Intra-pancreatic trypsinogen cleavage to proteolytic trypsin induces autodigestion and pancreatitis. In conclusion, this study finds a shared genetic predisposition between asparaginase-associated pancreatitis and non-asparaginase-associated pancreatitis, and targeting the trypsinogen activation pathway may enable identification of effective interventions for asparaginase-associated pancreatitis.
- Published
- 2019
15. Can Machine Learning Models Predict Asparaginase-associated Pancreatitis in Childhood Acute Lymphoblastic Leukemia
- Author
-
Ramneek Gupta, Marianne Helenius, Martin Stanulla, Thomas Frandsen, Line Katrine Harder Clemmensen, Rachita Yadav, Riitta Niinimäki, Sujith Samarasinghe, Jukka Kanerva, Benjamin Ole Wolthers, Anja Möricke, Morten Tulstrup, Birgitte Klug Albertsen, Rikke Linnemann Nielsen, Antonella Colombini, Shlomit Barzilai, Gabriele Escherich, Andishe Attarbaschi, Ester Zapotocka, Hsi-Che Liu, Inge M. van der Sluis, Kasper Nielsen, Kjeld Schmiegelow, Derya Aytan-Aktug, HUS Children and Adolescents, and Children's Hospital
- Subjects
Oncology ,medicine.medical_specialty ,Asparaginase ,3122 Cancers ,pediatric hematology/oncology ,Antineoplastic Agents ,acute lymphoblastic leukemia ,TOXICITY ,Machine Learning ,chemistry.chemical_compound ,Internal medicine ,medicine ,Humans ,Child ,Childhood Acute Lymphoblastic Leukemia ,POLYMORPHISMS ,RISK ,business.industry ,PRSS1-PRSS2 ,Hematology ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,artificial intelligence ,medicine.disease ,pediatric hematology ,translational research ,treatment toxicity ,chemistry ,Pancreatitis ,Pediatrics, Perinatology and Child Health ,business ,Genome-Wide Association Study - Abstract
Publisher Copyright: © 2021 Lippincott Williams and Wilkins. All rights reserved. Asparaginase-associated pancreatitis (AAP) frequently affects children treated for acute lymphoblastic leukemia (ALL) causing severe acute and persisting complications. Known risk factors such as asparaginase dosing, older age and single nucleotide polymorphisms (SNPs) have insufficient odds ratios to allow personalized asparaginase therapy. In this study, we explored machine learning strategies for prediction of individual AAP risk. We integrated information on age, sex, and SNPs based on Illumina Omni2.5exome-8 arrays of patients with childhood ALL (N=1564, 244 with AAP aged 1.0 to 17.9 y) from 10 international ALL consortia into machine learning models including regression, random forest, AdaBoost and artificial neural networks. A model with only age and sex had area under the receiver operating characteristic curve (ROC-AUC) of 0.62. Inclusion of 6 pancreatitis candidate gene SNPs or 4 validated pancreatitis SNPs boosted ROC-AUC somewhat (0.67) while 30 SNPs, identified through our AAP genome-wide association study cohort, boosted performance (0.80). Most predictive features included rs10273639 (PRSS1-PRSS2), rs10436957 (CTRC), rs13228878 (PRSS1/PRSS2), rs1505495 (GALNTL6), rs4655107 (EPHB2) and age (1 to 7 y). Second AAP following asparaginase re-exposure was predicted with ROC-AUC: 0.65. The machine learning models assist individual-level risk assessment of AAP for future prevention trials, and may legitimize asparaginase re-exposure when AAP risk is predicted to be low.
- Published
- 2021
16. Acute and persistent symptoms in non-hospitalized PCR-confirmed COVID-19 patients
- Author
-
Claus Henrik Nielsen, Karina Banasik, Frank Geller, Søren Brunak, David Westergaard, Morten Tulstrup, Bjarke Feenstra, Ioanna Nissen, Susanne Dam Nielsen, Kirsten Groenbaek, Lisa Cantwell, Sofie Bliddal, Ulla Feldt-Rasmussen, Ole Birger Pedersen, Niels Tommerup, Henrik Ullum, Sisse R. Ostrowski, and Michael Schwinn
- Subjects
medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Hospitalized patients ,business.industry ,Female sex ,Odds ratio ,Asymptomatic ,Disease Presentation ,Internal medicine ,medicine ,medicine.symptom ,Civil registration ,business ,Cohort study - Abstract
BackgroundReports of persistent symptoms after hospitalization with COVID-19 have raised concern of a “long COVID” syndrome. This study aimed at characterizing acute and persistent symptoms in non- hospitalized patients with polymerase chain reaction (PCR) confirmed COVID-19.MethodsCohort study of 445 non-hospitalized participants identified via the Danish Civil Registration System with a SARS-CoV-2-positive PCR-test and available biobank samples for genetic analyses. Participants received a digital questionnaire on demographics and COVID-19-related symptoms. Persistent symptoms: symptoms >four weeks (in sensitivity analyses >12 weeks).Results445 participants were included, of whom 34% were asymptomatic. Most common acute symptoms were fatigue, headache, and sneezing, while fatigue and reduced smell and taste were reported as most severe. Persistent symptoms, most commonly fatigue and memory and concentration difficulties, were reported by 36% of 198 symptomatic participants with follow-up >four weeks. Risk factors for persistent symptoms included female sex (women 44% vs. men 24%, odds ratio 2.7, 95%CI:1.4-5.1, p=0.003) and BMI (odds ratio 1.1, 95%CI:1.0-1.2, p=0.001).ConclusionAmong non-hospitalized PCR-confirmed COVID-19 patients one third were asymptomatic while one third of symptomatic participants had persistent symptoms illustrating the heterogeneity of disease presentation. These findings should be considered in future health care planning and policy making related to COVID-19.
- Published
- 2021
17. Effects ofNT5C2germline variants on 6-mecaptopurine metabolism in children with acute lymphoblastic leukemia
- Author
-
Takaya Moriyama, Kjeld Schmiegelow, Smita Bhatia, Ching-Hon Pui, Chuang Jiang, Wentao Yang, Morten Tulstrup, Jun J. Yang, Maoxiang Qian, Hui Zhang, Wenjian Yang, Chengcheng Liu, Mary V. Relling, Colton Smith, Ziping Li, Kristine R. Crews, and William E. Evans
- Subjects
Genetics ,chemistry.chemical_classification ,chemistry ,Lymphoblastic Leukemia ,Genetic variation ,NT5C2 Gene ,Nucleotide ,Single-nucleotide polymorphism ,Metabolism ,Biology ,Cytotoxicity ,Germline - Abstract
6-mercaptopurine (6-MP) is widely used in the treatment of acute lymphoblastic leukemia (ALL), and its cytotoxicity is primarily mediated by thioguanine nucleotide metabolites (TGN). Recent genome-wide association study has identified germline polymorphisms (e.g., rs72846714) in theNT5C2gene associated with 6-MP metabolism in patients with ALL. However, the full spectrum of genetic variation inNT5C2is unclear and its impact on 6-MP drug activation has not been comprehensively examined. To this end, we performed targeted sequencing ofNT5C2in 588 children with ALL and identified 121 single nucleotide polymorphisms (SNPs) nominally associated with erythrocyte TGN during 6-MP treatment (P< 0.05). Of these, 61 variants were validated in a replication cohort of 372 children with ALL. After considering linkage disequilibrium and multivariate analysis, we confirmed two clusters of variants, represented by rs72846714 and rs58700372, that independently affected 6-MP metabolism. Functional studies showed that rs58700372 directly altered the activity of an intronic enhancer, with the variant allele linked to higher transcription activity and reduced 6-MP metabolism (lower TGN). By contrast, rs72846714 was not located in a regulatory element and instead its association signal was explained by linkage disequilibrium with a proximal functional variant rs12256506 that activatedNT5C2transcription in-cis. Our results indicated thatNT5C2germline variation significantly contributes to inter-patient variability in thiopurine drug disposition.
- Published
- 2020
18. Genetic predisposition to PEG-asparaginase hypersensitivity in children treated according to NOPHO ALL2008
- Author
-
Ramneek Gupta, Goda Vaitkeviciene, Louise Tram Henriksen, Arja Harila-Saari, Jonas Abrahamsson, Sofie Gottschalk Højfeldt, Mats Heyman, Olafur G. Jonsson, Birgitte Klug Albertsen, Benjamin Ole Wolthers, Päivi M. Lähteenmäki, Kjeld Schmiegelow, Bendik Lund, Kaie Pruunsild, and Morten Tulstrup
- Subjects
Male ,Allergy ,Asparaginase ,Adolescent ,Genome-wide association study ,Human leukocyte antigen ,PEG-asparaginase ,Polyethylene Glycols ,Drug Hypersensitivity ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,ATP Binding Cassette Transporter, Subfamily B, Member 3 ,HLA-DQ Antigens ,Antineoplastic Combined Chemotherapy Protocols ,Genetic predisposition ,Medicine ,Humans ,Genetic Predisposition to Disease ,Child ,genome-wide association study ,biology ,business.industry ,Genetic Variation ,Infant ,Hematology ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,medicine.disease ,ta3123 ,Enzyme assay ,Neoplasm Proteins ,paediatric acute lymphoblastic leukaemia ,chemistry ,030220 oncology & carcinogenesis ,Child, Preschool ,Immunology ,Toxicity ,biology.protein ,TAP2 ,Chromosomes, Human, Pair 6 ,Female ,hypersensitivity ,business ,Chromosomes, Human, Pair 19 ,030215 immunology ,Genome-Wide Association Study ,Transcription Factors - Abstract
Asparaginase is essential in childhood acute lymphoblastic leukaemia (ALL) treatment, however hypersensitivity reactions to pegylated asparaginase (PEG-asparaginase) hampers anti-neoplastic efficacy. Patients with PEG-asparaginase hypersensitivity have been shown to possess zero asparaginase enzyme activity. Using this measurement to define the phenotype, we investigated genetic predisposition to PEG-asparaginase hypersensitivity in a genome-wide association study (GWAS). From July 2008 to March 2016, 1494 children were treated on the Nordic Society of Paediatric Haematology and Oncology ALL2008 protocol. Cases were defined by clinical hypersensitivity and no enzyme activity, controls had enzyme activity ≥ 100 iu/l and no hypersensitivity symptoms. PEG-asparaginase hypersensitivity was reported in 13·8% (206/1494) of patients. Fifty-nine cases and 772 controls fulfilled GWAS inclusion criteria. The CNOT3 variant rs73062673 on 19q13.42, was associated with PEG-asparaginase allergy (P = 4·68 × 10-8 ). We further identified two signals on chromosome 6 in relation to HLA-DQA1 (P = 9·37 × 10-6 ) and TAP2 (P = 1·59 × 10-5 ). This study associated variants in CNOT3 and in the human leucocyte antigen (HLA) region with PEG-asparaginase hypersensitivity, suggesting that not only genetic variations in the HLA region, but also regulation of these genes are of importance in the biology of this toxicity. Furthermore, our study emphasizes the importance of using asparaginase enzyme activity measurements to identify PEG-asparaginase hypersensitivity.
- Published
- 2019
19. Parents’ and Adolescents’ Preferences for Intensified or Reduced Treatment in Randomized Lymphoblastic Leukemia Trials
- Author
-
Birgitte Klug Albertsen, Jonas Abrahamsson, Ann Åsberg, Peter Rossel, Kathrine Grell, Olafur Gisli Jonsson, Hanne Bækgaard Larsen, Morten Tulstrup, Anders Castor, Thomas Frandsen, Kim Vettenranta, Stefan Söderhäll, Mats Heyman, and Kjeld Schmiegelow
- Subjects
Disease free survival ,Pediatrics ,medicine.medical_specialty ,business.industry ,Lymphoblastic Leukemia ,Cancer ,Hematology ,medicine.disease ,Patient preference ,Clinical trial ,Precursor Cell Lymphoblastic Leukemia Lymphoma ,03 medical and health sciences ,0302 clinical medicine ,Oncology ,Treatment Refusal ,030220 oncology & carcinogenesis ,Pediatrics, Perinatology and Child Health ,Physical therapy ,Medicine ,030212 general & internal medicine ,business ,Survival rate - Abstract
When offered participation in clinical trials, families of children with cancer face a delicate balance between cure and toxicity. Since parents and children may perceive this balance differently, this paper explores whether adolescent patients have different enrollment patterns compared to younger children in trials with different toxicity profiles.
- Published
- 2015
20. Genome-Wide Association Meta-Analysis of Single-Nucleotide Polymorphisms and Symptomatic Venous Thromboembolism during Therapy for Acute Lymphoblastic Leukemia and Lymphoma in Caucasian Children
- Author
-
Pasquale M Barbaro, Michael C.J. Quinn, Ramneek Gupta, Chelsea Mayoh, Luciano Dalla-Pozza, Glenn M. Marshall, Tamas Revesz, Francoise Mechinaud, Benjamin Ole Wolthers, Ulf Tedgård, Stuart MacGregor, Kjeld Schmiegelow, Morten Tulstrup, Pasi Huttunen, Kadri Saks, Rosemary Sutton, Frank Alvaro, Daniel Catchpoole, Georgia Chenevix-Trench, Marion K. Mateos, Olafur G. Jonsson, Toby Trahair, Draga Barbaric, Ruta Tuckuviene, Rishi S. Kotecha, Ellen Ruud, Sonata Saulyte Trakymiene, Jodie E. Giles, HUS Comprehensive Cancer Center, HUS Children and Adolescents, Clinicum, Children's Hospital, and Helsinki University Hospital Area
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,MULTICENTER ,Genome-wide association study ,Disease ,Acute lymphoblastic leukemia ,DISEASE ,Coronary artery disease ,0302 clinical medicine ,3123 Gynaecology and paediatrics ,GENETIC-VARIANTS ,hemic and lymphatic diseases ,KALIRIN ,Child ,Single-nucleotide polymorphism ,RISK ,child ,CHEMOTHERAPY ,single-nucleotide polymorphism ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,3. Good health ,030220 oncology & carcinogenesis ,Meta-analysis ,Cohort ,Medical genetics ,acute lymphoblastic leukemia ,genome-wide association study ,venous thromboembolism ,Venous thromboembolism ,medicine.medical_specialty ,PEDIATRIC HEMATOLOGY ,3122 Cancers ,INHIBITION ,lcsh:RC254-282 ,Article ,03 medical and health sciences ,Internal medicine ,Genetic predisposition ,medicine ,1112 Oncology and Carcinogenesis ,business.industry ,medicine.disease ,INDIVIDUALS ,030104 developmental biology ,business ,NORDIC SOCIETY - Abstract
Symptomatic venous thromboembolism (VTE) occurs in five percent of children treated for acute lymphoblastic leukemia (ALL), but whether a genetic predisposition exists across different ALL treatment regimens has not been well studied. Methods: We undertook a genome-wide association study (GWAS) meta-analysis for VTE in consecutively treated children in the Nordic/Baltic acute lymphoblastic leukemia 2008 (ALL2008) cohort and the Australian Evaluation of Risk of ALL Treatment-Related Side-Effects (ERASE) cohort. A total of 92 cases and 1481 controls of European ancestry were included. Results: No SNPs reached genome-wide significance (p <, 5 ×, 10&minus, 8) in either cohort. Among the top 34 single-nucleotide polymorphisms (SNPs) (p <, 1 ×, 6), two loci had concordant effects in both cohorts: ALOX15B (rs1804772) (MAF: 1%, p = 3.95 ×, 7) that influences arachidonic acid metabolism and thus platelet aggregation, and KALRN (rs570684) (MAF: 1%, p = 4.34 ×, 7) that has been previously associated with risk of ischemic stroke, atherosclerosis, and early-onset coronary artery disease. Conclusion: This represents the largest GWAS meta-analysis conducted to date associating SNPs to VTE in children and adolescents treated on childhood ALL protocols. Validation of these findings is needed and may then lead to patient stratification for VTE preventive interventions. As VTE hemostasis involves multiple pathways, a more powerful GWAS is needed to detect combination of variants associated with VTE.
- Published
- 2020
21. NT5C2 germline variants alter thiopurine metabolism and are associated with acquired NT5C2 relapse mutations in childhood acute lymphoblastic leukaemia
- Author
-
Erik Hulegårdh, Bendik Lund, Marie Grosjean, Ramneek Gupta, Morten Tulstrup, William L. Carroll, Kaie Pruunsild, Jacob Nersting, Zeyu Zhang, Marlene Danner Dalgaard, Nina Toft, Peder Skov Wegener, Mari Punab, Goda Vaitkeviciene, Jinhua Wang, Kathrine Grell, Stine Nygaard Nielsen, Sigurd Liestol, Olafur G. Jonsson, Benjamin Ole Wolthers, Laimonas Griskevicius, Arja Harila-Saari, Jonas Abrahamsson, Mette Holm, and Kjeld Schmiegelow
- Subjects
0301 basic medicine ,Oncology ,Male ,Cancer Research ,medicine.medical_specialty ,Antimetabolites, Antineoplastic ,Adolescent ,Genotype ,Single-nucleotide polymorphism ,Polymorphism, Single Nucleotide ,Germline ,03 medical and health sciences ,0302 clinical medicine ,Maintenance therapy ,Gene Frequency ,Polymorphism (computer science) ,Recurrence ,Internal medicine ,medicine ,Humans ,Child ,Thioguanine ,5'-Nucleotidase ,Genetic association ,Thiopurine methyltransferase ,biology ,business.industry ,Mercaptopurine ,Infant ,Hematology ,DNA ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Minor allele frequency ,030104 developmental biology ,Germ Cells ,030220 oncology & carcinogenesis ,Child, Preschool ,biology.protein ,Female ,Neoplasm Recurrence, Local ,business ,Genome-Wide Association Study - Abstract
The antileukaemic drug 6-mercaptopurine is converted into thioguanine nucleotides (TGN) and incorporated into DNA (DNA-TG), the active end metabolite. In a series of genome-wide association studies, we analysed time-weighted means (wm) of erythrocyte concentrations of TGN (Ery-TGN) and DNA-TG in 1009 patients undergoing maintenance therapy for acute lymphoblastic leukaemia (ALL). In discovery analyses (454 patients), the propensity for DNA-TG incorporation (wmDNA-TG/wmEry-TGN ratio) was significantly associated with three intronic SNPs in NT5C2 (top hit: rs72846714; P = 2.09 × 10−10, minor allele frequency 15%). In validation analyses (555 patients), this association remained significant during both early and late maintenance therapy (P = 8.4 × 10−6 and 1.3 × 10−3, respectively). The association was mostly driven by differences in wmEry-TGN, but in regression analyses adjusted for wmEry-TGN (P < 0.0001), rs72846714-A genotype was also associated with a higher wmDNA-TG (P = 0.029). Targeted sequencing of NT5C2 did not identify any missense variants associated with rs72846714 or wmEry-TGN/wmDNA-TG. rs72846714 was not associated with relapse risk, but in a separate cohort of 180 children with relapsed ALL, rs72846714-A genotype was associated with increased occurrence of relapse-specific NT5C2 gain-of-function mutations that reduce cytosol TGN levels (P = 0.03). These observations highlight the impact of both germline and acquired mutations in drug metabolism and disease trajectory.
- Published
- 2018
22. Individualized 6-mercaptopurine increments in consolidation treatment of childhood acute lymphoblastic leukemia:A NOPHO randomized controlled trial
- Author
-
Olafur G. Jonsson, Mats Heyman, Jonas Abrahamsson, Bendik Lund, Kim Vettenranta, Hanne Vibeke Marquart, Birgitte Klug Albertsen, Thomas Frandsen, Kjeld Schmiegelow, and Morten Tulstrup
- Subjects
0301 basic medicine ,Male ,medicine.medical_specialty ,Antimetabolites, Antineoplastic ,Neoplasm, Residual ,Lymphoblastic Leukemia ,acute lymphoblastic leukemia ,law.invention ,Consolidation therapy ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,children ,law ,Internal medicine ,Odds Ratio ,Medicine ,Humans ,6-mercaptopurine ,Child ,Childhood Acute Lymphoblastic Leukemia ,business.industry ,Mercaptopurine ,Hematology ,General Medicine ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Minimal residual disease ,Survival Analysis ,Surgery ,Blood Cell Count ,Consolidation Chemotherapy ,030104 developmental biology ,Treatment Outcome ,030220 oncology & carcinogenesis ,Child, Preschool ,Retreatment ,randomized controlled trial ,Female ,business ,consolidation therapy ,Standard therapy ,Biomarkers ,medicine.drug - Abstract
Objectives This randomized controlled trial tested the hypothesis that children with non-high risk acute lymphoblastic leukemia could benefit from individualized 6-mercaptopurine increments during consolidation therapy (NCT00816049). Primary and secondary end points were end of consolidation minimal residual disease (MRD) positivity and event-free survival. Methods 392 patients were randomized to experimental and 396 to standard therapy. Patients allocated to standard therapy received oral 6-mercaptopurine (25 mg/m2/day) from days 30 to 85, while the experimental arm received stepwise increments of additional 25 mg/m2/day beginning on days 50 and/or 71 unless dose-limiting myelosuppression had occurred. Results In the experimental arm, 166 patients (42%) received one dose increment, and 62 (16%) received two. 57 of 387 (15%) in the experimental arm were MRD positive at end of consolidation versus 77 of 389 (20%) in the control arm (P=0.08). Five-year probability of event-free survival was 0.89 (95% CI: 0.85–0.93) in the experimental arm versus 0.93 (0.90–0.96) in the control arm (P=0.13). The median accumulated length of 6-mercaptopurine treatment interruptions was 7 (IQR 2–12) in the experimental arm versus 4 (IQR 0–10) in the control arm (P=0.002). Conclusion This study found no benefit from individualized 6-mercaptopurine increments compared to standard therapy. This article is protected by copyright. All rights reserved.
- Published
- 2018
23. A qualitative study of decision-making on Phase III randomized clinical trial participation in paediatric oncology: Adolescents' and parents' perspectives and preferences
- Author
-
Kjeld Schmiegelow, Morten Tulstrup, Hanne Bækgaard Larsen, and Marianne Vie Ingersgaard
- Subjects
Adult ,Male ,Parents ,Adolescent ,Decision Making ,Exploratory research ,Antineoplastic Agents ,law.invention ,Polyethylene Glycols ,Interviews as Topic ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,Medicine ,Asparaginase ,Humans ,030212 general & internal medicine ,Child ,General Nursing ,Qualitative Research ,business.industry ,Paediatric oncology ,Mercaptopurine ,Nursing research ,Uncertainty ,Infant ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Clinical trial ,Survival Rate ,Distress ,Content analysis ,030220 oncology & carcinogenesis ,Child, Preschool ,Female ,Patient Participation ,business ,Clinical psychology ,Qualitative research - Abstract
Aim To explore parents’ and adolescents’ motives for accepting/declining participation in the ALL2008 trials and adolescents’ involvement in the decision-making process. Background Children and adolescents with acute lymphoblastic leukemia treated on the Nordic Society of Paediatric Haematology and Oncology ALL2008 protocol were eligible for two randomizations testing 6-mercaptopurine treatment intensifications to improve efficacy and Asparaginase de-escalation to reduce toxicity. We recently reported that while adolescents favored treatment reduction, parents of young children favored treatment intensification. Design A qualitative, exploratory study. Methods A maximum variation sampling strategy was used. Five adolescents aged 12–17 years, six parents of adolescents and five parents of children aged 1-12 years were interviewed in the period March to May 2015. Data were analyzed using content analysis. Findings Adolescents and parents emphasized the importance of adolescents’ active participation in decisions regarding enrollment into clinical trials. A majority of adolescents were either final or collaborative decision-makers. Parents stated that in case of disagreement they would overrule the adolescents’ decision. There were no differences between motivations of preferences held by parents of children or adolescents, respectively. Decisions were based on subjective values attributed to cure contra toxicity and individual preferences for either standard or experimental treatment. The possibility of a negative outcome induced fear of decisional regret and distress by the parents, yet they invested considerable trust in the physician's expertise. Conclusion Our findings highlight the importance of adolescents’ active involvement in consent conferences. Research on management of disagreements between adolescents and parents in trial decisions is needed. This article is protected by copyright. All rights reserved.
- Published
- 2017
24. Epidemiology and Etiology of Childhood ALL
- Author
-
Morten Tulstrup, Jun J. Yang, Ulrik Stoltze, and Kjeld Schmiegelow
- Subjects
0301 basic medicine ,medicine.medical_specialty ,business.industry ,medicine.disease ,Bioinformatics ,Germline ,03 medical and health sciences ,Haematopoiesis ,030104 developmental biology ,0302 clinical medicine ,Fanconi anemia ,030220 oncology & carcinogenesis ,Precursor cell ,Epidemiology ,medicine ,Etiology ,business ,Childhood Acute Lymphoblastic Leukemia ,Nijmegen breakage syndrome - Abstract
Despite extensive research, the etiology of childhood acute lymphoblastic leukemia (ALL) remains largely unknown. There is growing evidence that childhood ALL arises from in utero chromosomal abnormalities that can lead to clonal expansion of pre-leukemic precursor cells. The risk factors for ALL in children are multiple, most notably common germline polymorphisms and rare genetic syndromes that directly influence hematopoiesis and cell cycling, as well as infection-related aberrant DNA editing.
- Published
- 2017
25. Single Nucleotide Polymorphisms and Thromboembolism in Acute Lymphoblastic Leukemia — a NOPHO ALL2008 Study
- Author
-
Morten Tulstrup, Kirsten Brunsvig Jarvis, Susanna Ranta, Marissa Le Blanc, Ruta Tuckuviene, Ellen Ruud, and Kjeld Schmiegelow
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Framingham Risk Score ,Proportional hazards model ,business.industry ,Immunology ,Hazard ratio ,Single-nucleotide polymorphism ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,Asymptomatic ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,030220 oncology & carcinogenesis ,ABO blood group system ,Internal medicine ,Acute lymphocytic leukemia ,medicine ,Cumulative incidence ,medicine.symptom ,business - Abstract
Introduction: Thromboembolism (TE) is a major toxicity of acute lymphoblastic leukemia (ALL) treatment and contributes to substantial morbidity and mortality. Several germline DNA variants have been associated with TE in adults without cancer. A meta-analysis of genome-wide association studies on TE by Germain et al. (Am J Hum Genet 2015) identified single nucleotide polymorphisms (SNPs) in 8 genes that contribute to increased risk of TE in adults (ABO,F2, F5,F11, FGG,PROCR,TSPAN15, and SLC44A2). De Haan et al. (Blood 2012) found that SNPs in 5 of these (F5, F2, F11, FGG, and ABO) predicted TE almost as well as a 31 SNP-based risk score. However, the impact of these SNPs in patients with cancer, particularly in children, remains uncertain. Materials and methods: The Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL2008 protocol for children and adults (1-45 years) included a 3-drug induction (vincristine, doxorubicin, glucocorticosteroid) followed by exposure to asparaginase (1,000 IU/m.sq. i.m.) from week 5 until week 33 (details of therapy in Toft, Leukemia 2018). We collected germline DNA and prospectively registered TE events on 1482 children and adults diagnosed with ALL and treated according to the ALL2008 protocol in seven Nordic and Baltic countries (7/2008-7/2016) (Rank, Blood 2018). Inclusion criteria for TE were i) symptomatic venous or arterial TE confirmed by imaging or by autopsy for TE diagnosed post mortem or ii) asymptomatic TE confirmed by imaging due to other non-TE symptoms and treated with systemic anticoagulation. Based on previously published data and a priori power calculations, we selected and genotyped 5 SNPs: F5 rs6025 (risk allele frequency (RAF) 0.05), F11 rs2036914 (RAF 0.52), FGG rs2066865 (RAF 0.22), and ABO SNPs rs8176719 (RAF 0.39) and rs2519093 (RAF 0.24). Three SNPs (F5 and the two ABO SNPs) were found by imputation, which was done on a subset of patients with European ancestry and included in the NOPHO ALL2008 protocol (N = 1229). We constructed genetic risk scores using a combination of the SNPs. Results: During the ALL treatment period 107 of 1482 patients developed TE (2.5-year cumulative incidence 7.3%, 95% confidence interval (CI) 5.9-8.5). In multivariate Cox regression analysis controlling for age, gender, presence of mediastinal mass and enlarged lymph nodes (N = 1192, whereof TE events 84), we found statistically significant associations with TE development for SNPs F5 rs6025 (hazard ratio (HR) 2.96, 95% CI 1.59-5.48), F11 rs2036914 (HR 1.62, 95% CI 1.18-2.24), and FGG rs2066865 (HR 1.40 95% CI 1.01-1.95), whereas there were no significant associations with ABO SNPs rs8176719 (HR 0.98, 95% CI 0.64-1.51) or rs2519093 (HR 1.06, 95% CI 0.65-1.73). An unweighted 3 SNP risk score based on SNPs F5, F11, and FGG was associated with TE development (HR 1.59, 95% CI 1.27-1.98) (Figure 1). Twenty-six of 217 patients with ≥3 risk alleles developed TE (12.0%, 95% CI 8.1-17.2), compared to 62 of 1007 patients with 18 years) the proportion who developed TE was quite high in both the group with ≥3 risk alleles (23.5%, 95% CI 7.8-50.2) and with Conclusion: Based on the strong association between F5 rs6025, F11 rs2036914, and FGG rs2066865 and TE development, not least for adolescents, future preventive measures for TE should target adolescents with ≥3 risk alleles as well as any adults ≥18 years. Disclosures No relevant conflicts of interest to declare.
- Published
- 2018
26. Asparaginase-associated pancreatitis: a study on phenotype and genotype in the NOPHO ALL2008 protocol
- Author
-
Morten Tulstrup, Olafur G. Jonsson, Thomas Frandsen, Rachita Yadav, Birgitte Klug Albertsen, Goda Vaitkevičienė, Kirsten K. Rasmussen, Ramneek Gupta, Louise Rold Helt, Raheel Altaf Raja, L T Kõrgvee, Mervi Taskinen, Benjamin Ole Wolthers, M. Heyman, Bendik Lund, Kjeld Schmiegelow, and Jonas Abrahamsson
- Subjects
0301 basic medicine ,Male ,Cancer Research ,Asparaginase ,medicine.medical_specialty ,Adolescent ,Genotype ,Antineoplastic Agents ,Protein Serine-Threonine Kinases ,Lower risk ,Gastroenterology ,Polymorphism, Single Nucleotide ,Severity of Illness Index ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Gene Frequency ,Internal medicine ,Severity of illness ,medicine ,Odds Ratio ,Humans ,Cumulative incidence ,Child ,Alleles ,Genetic Association Studies ,business.industry ,Case-control study ,Infant ,Hematology ,Odds ratio ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,medicine.disease ,Surgery ,Leukemia ,030104 developmental biology ,Phenotype ,Oncology ,chemistry ,Pancreatitis ,030220 oncology & carcinogenesis ,Case-Control Studies ,Child, Preschool ,Female ,business ,Biomarkers - Abstract
Asparaginase (ASP)-associated pancreatitis (AAP) occurs during acute lymphoblastic leukemia treatment. Among 1285 children (1.0-17.9 years) diagnosed during July 2008-December 2014 and treated according to the Nordic/Baltic ALL2008 protocol, 86 (cumulative incidence=6.8%) developed AAP. Seventy-three cases were severe (diagnostic AAP criteria persisting >72 h) and 13 mild. Cases were older than controls (median: 6.5 vs 4.5 years; P=0.001). Pseudocysts developed in 28%. Of the 20 re-exposed to ASP, 9 (45%) developed a second AAP. After a median follow-up of 2.3 years, 8% needed permanent insulin therapy, and 7% had recurrent abdominal pain. Germline DNA on 62 cases and 638 controls was genotyped on Omni2.5exome-8-v1.2 BeadChip arrays. Overall, the ULK2 variant rs281366 showed the strongest association with AAP (P=5.8 × 10(-7); odds ratio (OR)=6.7). Cases with the rs281366 variant were younger (4.3 vs 8 years; P=0.015) and had lower risk of AAP-related complications (15% vs 43%; P=0.13) compared with cases without this variant. Among 45 cases and 517 controls
- Published
- 2016
27. Common Genetic Variants in Trypsin Regulating Genes Are Associated with AsparAginase-Associated Pancreatitis in Children with Acute Lymphoblastic Leukemia: A Ponte Di Legno Toxicity Working Group Study
- Author
-
Kjeld Schmiegelow, Ramneek Gupta, Der-Cherng Liang, Inge M. van der Sluis, Gabriele Escherich, Sujith Samarasinghe, Anja Möricke, Antonella Colombini, Thomas Frandsen, Chirag J. Patel, Shlomit Barzilai, Kirsten K. Rasmussen, Andishe Attarbaschi, Ester Zapotocka, Marie Grosjean, Morten Tulstrup, Benjamin Ole Wolthers, and Martin Stanulla
- Subjects
medicine.medical_specialty ,Hereditary pancreatitis ,business.industry ,Trypsinogen ,Immunology ,Single-nucleotide polymorphism ,Cell Biology ,Hematology ,Odds ratio ,medicine.disease ,Biochemistry ,Gastroenterology ,Minor allele frequency ,chemistry.chemical_compound ,chemistry ,Internal medicine ,Genotype ,Medicine ,Pancreatitis ,Allele ,business - Abstract
Background: Asparaginase-associated pancreatitis (AAP) is a well-known toxicity of childhood acute lymphoblastic leukemia (ALL) therapy. Recent multi-trial group phenotyping of 465AAP caseshas documented severe complications to AAP, including 8% risk of needing assisted mechanical ventilation, 26% risk of developing pancreatic pseudocysts and 9% risk of developing persisting diabetes (Wolthers et al. Lancet Oncology, 2017) . Investigation of host genome variation associated with AAP has been limited by varying phenotype definition, inclusion criteria and small study sizes. Objectives and Methods: To investigate genetic variants associated with risk of developing AAP, this genome-wide association study reports data on 1544 children (1.0−17.9 years) from 10 ALL trial groups treated with ALL from January 2000−January 2016. The Ponte di Legno toxicity working group consensus definition (Schmiegelow et al. Lancet Oncology, 2016) was used to diagnose AAP: At least two of i) amylase, pancreatic amylase, or pancreatic lipase >3x upper normal limit (UNL), ii) abdominal pain, iii) imaging compatible with AAP. Controls included children treated for ALL with verified completion of intended asparaginase therapy, 78% of whom (1024/1320) received at least 8 injections of PEG-asparaginase without developing AAP. Germline DNA obtained after clinical remission was genotyped on Illumina Infinium Omni2.5exome-8 BeadChip arrays. Association analyses were done in PLINK and annotation in Ensembl. Results: Of 1564 patients passing genotype quality control, 244 had AAP. 205 of 244 (84%) of cases and 1185/1320 (90%) of controls were of European ancestry. Median age was 8.1 years (IQR 4.3−13.1) and 5 (IQR: 3−9) for cases and controls, respectively. After filtering, 1401908 single nucleotide polymorphisms (SNPs) with a minor allele frequency above 1% were analyzed. In logistic regression analysis, adjusting for age and ancestry, the variant rs62228256 (reference allele=C, minor allele=T (C>T)) on 20q13.2 had the strongest association to AAP (OR=3.75; 95% CI 2.33−6.04; p=5.2∙10-8). rs62228256 is located in a non-coding region without known regulatory effects. rs13228878 (A>G; OR=0.61; 95% CI 0.5−0.76; p=7.1∙10-6) and rs10273639 (C>T; OR=0.62; 95% CI 0.5−0.77; p =1.1∙10-5) were among the top 30 SNPs most significantly associated to AAP. They are in high linkage disequilibrium (R2=0.94) and located in the PRSS1-PRSS2 locus on chromosome 7. The rs13228878 A risk allele was not associated with level of amylase (p=0.1) or lipase (p=0,68) at diagnosis of AAP, age at diagnosis of AAP (p=0.63), or risk of pseudocysts (p=0.78). Using identical diagnostic criteria for pancreatitis, the major C allele in rs10273639 has been associated with pancreatitis risk in adults (Whitcomb et al. Nature Genetics, 2012; Masson et al. Gut, 2017) with identical risk allele and similar odds ratios. PRSS1 and PRSS2 encode cationic and anionic trypsinogen, respectively. rs10273639 is an expressive quantitative locus for PRSS1 and the C risk-variant is associated with elevated expression of trypsinogen in pancreatic tissue. Gain of function mutations in PRSS1, known from hereditary pancreatitis, lead to increased autoactivation, increased intra-acinar trypsin levels, and increased risk of auto-digestion leading to pancreatitis. Further investigation of previously validated SNPs known to regulate trypsin activation gave the following results for associations with AAP; rs17107315 in pancreatic secretory trypsin inhibitor (SPINK1; OR=2.87; 95% CI 1.36−5.8; p=4∙10-3), rs10436957 in chymotrypsin C (CTRC ; OR=0.69; 95% CI 0.53−0.89; p=5∙10-3) and rs4409525 in Claudin-2 (CLDN2 ; OR=1.41; 95% CI 1.08−1.83; p=1∙10-2). In total, 207 out of 244 cases were homozygous for the risk allele in rs13228878 (n=104), rs17107315 (n=1), rs10436957 (n=165) and/or rs4409525 (n=16). However, no significant additive effect of having more than one risk allele was found. Conclusion: Children who develop AAP possess the same pancreatitis risk variants as adults with non-asparaginase associated pancreatitis. This shared genetic disposition may facilitate research into pathogenesis and identification of effective interventions towards AAP. Disclosures No relevant conflicts of interest to declare.
- Published
- 2017
28. Parents' and Adolescents' Preferences for Intensified or Reduced Treatment in Randomized Lymphoblastic Leukemia Trials
- Author
-
Morten, Tulstrup, Hanne Baekgaard, Larsen, Anders, Castor, Peter, Rossel, Kathrine, Grell, Mats, Heyman, Jonas, Abrahamsson, Stefan, Söderhäll, Ann, Åsberg, Olafur Gisli, Jonsson, Kim, Vettenranta, Thomas Leth, Frandsen, Birgitte Klug, Albertsen, and Kjeld, Schmiegelow
- Subjects
Adult ,Male ,Parents ,Adolescent ,Mercaptopurine ,Patient Preference ,Middle Aged ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Dexamethasone ,Disease-Free Survival ,Polyethylene Glycols ,Survival Rate ,Treatment Refusal ,Vincristine ,Antineoplastic Combined Chemotherapy Protocols ,Asparaginase ,Humans ,Female - Abstract
When offered participation in clinical trials, families of children with cancer face a delicate balance between cure and toxicity. Since parents and children may perceive this balance differently, this paper explores whether adolescent patients have different enrollment patterns compared to younger children in trials with different toxicity profiles.Age-dependent participation rates in three consecutive, randomized childhood leukemia trials conducted by the Nordic Society of Paediatric Haematology and Oncology were evaluated. The ALL2000 dexamethasone/vincristine (Dx/VCR) trial tested treatment intensifications to improve cure, and the back-to-back ALL2008 6-mercaptopurine (6MP) and ALL2008 PEG-asparaginase (ASP) trials tested treatment intensifications (6MP) and toxicity reduction without compromising survival (ASP). Patient randomization and toxicity data were prospectively registered by the treating physicians.Parents of young children favored treatment intensifications (Dx/VCR: 12% refusal; 6MP: 14%; ASP: 21%), whereas parents of adolescents favored treatment reductions (Dx/VCR: 52% refusal; 6MP: 30%; ASP: 8%). Adolescents were more likely to refuse intensification trials than young children (adjusted ORs 6.3; P0.01 [Dx/VCR] and 2.1; P = 0.04 [6MP]). Adolescents were less likely to refuse the ASP trial, with varying effect size depending on the length of the preceding consolidation treatment (adjusted OR for median consolidation length 0.15; P = 0.01). Younger children participated more frequently in only 6MP than in only ASP (14% vs. 5%), and adolescents vice versa (2% vs. 17%; P = 0.001).Parents' and adolescents' divergent inclinations toward intensified or reduced therapy emphasize the necessity of actively involving adolescents in the informed consent process, which should also address motives for trial participation.
- Published
- 2015
29. Single Nucleotide Polymorphisms and Thromboembolism in Acute Lymphoblastic Leukemia – A NOPHO ALL2008 Study
- Author
-
Kirsten Brunsvig Jarvis, Marissa le Blanc, Morten Tulstrup, Rikke Nielsen, Birgitte Klug Albertsen, Ramneek Gupta, Ellen Ruud, Ruta Tuckuviene, Susanna Ranta, and Kjeld Schmiegelow
- Subjects
hemic and lymphatic diseases ,hemic and immune systems - Abstract
Single Nucleotide Polymorphisms and Thromboembolism in Acute Lymphoblastic Leukemia – A NOPHO ALL2008 Study
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.